Type 2 diabetes mellitus management and body mass index: experiences with initiating insulin detemir in the a1chieve study.

ABSTRACT:

Introduction

This sub-analysis of the A1chieve study aimed to examine the safety and efficacy of insulin detemir (IDet) initiation over 24 weeks in relation to baseline body mass index (BMI) in people with type 2 diabetes mellitus (T2DM).

Methods

A1chieve was a 24-week non-interventional study to assess the safety and efficacy of insulin analogs in routine practice. This sub-analysis included insulin-naïve patients who initiated IDet therapy based on their physicians' decision. Patients were stratified according to baseline BMI (Group I, <25.0 kg/m(2); Group II, 25.0 to <30.0 kg/m(2); Group III, 30.0 to <35.0 kg/m(2); Group IV ≥35.0 kg/m(2)). Safety and efficacy variables were assessed over 24 weeks.

Results

Overall, 10,650 insulin-naïve patients were included (3,045

SUBMITTER: Khamseh ME 

PROVIDER: S-EPMC4065301 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature